The critical role of automation in CAR-T cell manufacturing
Automating the manufacturing process of a cell-based therapy is not a one-time event. Rather, it is a step-by-step, highly strategic process that is guided by a deep understanding of critical process parameters and the critical quality attributes of the resulting drug product. As understanding (and confidence in efficacy) evolves through positive clinical testing, so does confidence in receiving a positive return on investment. This presentation will describe the rationale and supporting data which guided the strategic automation of the CTL019 manufacturing process and associated analytics.
Rodney L. Rietze, Ph.D. -
Bioprocess Science and Innovation, Exploratory Immuno-Oncology,
Novartis Institutes for Biomedical Research